Shows
The Lumara SeriesEpisode 8: Launching Lumara –– What Success Could Look LikeLaunching Lumara — What Success Could Look LikeEpisode 8 brings the series together with a pragmatic launch integration plan: how a specialty biologic turns strategy into day-one execution. We outline the success factors that consistently separate winners: clear, payer-oriented messaging; layered evidence with early RWE; real-time competitive response; cross-TA access innovation; and tight alignment across Access, HEOR, Medical, and Field. You’ll hear how Lumara’s team pressure-tests readiness with a pre-mortem mindset and a facilitated dry run—logging risks, owners, and mitigations so the first 60 days move on signal, not scramble.What you’ll l...
2025-11-2408 minThe Lumara SeriesEpisode 7: Lessons from Elsewhere — What Other TAs Are Doing BetterLessons from Elsewhere — What Other TAs Are Doing BetterEpisode 7 looks outside severe asthma to borrow what works in oncology, migraine, and rare disease—and translate those access innovations to Lumara’s launch. We break down biomarker-tiered approaches and predictive outcome modeling from oncology; responder-based, modular reimbursement and pharmacy-channel starter kits from migraine; and concierge-style support with seamless financial triage from rare diseases. Then we map what’s portable, what’s risky, and where to pilot first.What you’ll learnWhich cross-TA tactics actually move access: biomarker-stratified messaging, responder-trial periods, and...
2025-11-1713 minThe Lumara SeriesEpisode 6: The Unknown Unknowns -- How Much Intel Are Your Competitors Gathering?The Unknown Unknowns — How Much Intel Are Your Competitors Gathering?Episode 6 pulls back the curtain on competitive intelligence (CI) maturity in severe asthma launches—what top teams track, how fast they learn, and why it matters for pricing, access, messaging, and patient support. We contrast integrated, always-on CI programs with reactive, vendor-only approaches, and show how social listening, field feedback loops, KOL digital patterns, and payer advisory monitoring translate into real decisions. You’ll also hear the most common failure points—time lag from signal to action, siloed insights, and low field trust—and how Lumara can...
2025-11-1011 minThe Lumara SeriesEpisode 5: Scaling the Access Wall –– Real-World Evidence as a DifferentiatorEpisode 5: Scaling the Access Wall — Real-World Evidence as a DifferentiatorIn episode 5, we explore how real-world evidence (RWE) has become the currency of access decisions. Beyond trials, payers want proof in routine care—on exacerbations, persistence, and healthcare utilization—and they use it for formulary positioning and renewal negotiations. We compare how leading severe-asthma brands deploy RWE today (e.g., registry analyses, integrated claims/EMR studies, regional dashboards) and outline Lumara’s options nine to twelve months pre-launch: claims/EMR partnerships, a purpose-built observational cohort, peer-reviewed publications and reprints, and interactive budget-impact tools for field teams. W...
2025-11-0309 minThe Lumara SeriesEpisode 4: Message Battles –– What Are Competitors Telling Payers (and How)?Purpose of Episode:In Episode 4 we'll explore how existing brands in the Severe Asthma market are positioning their value stories to payers — in both economic and clinical terms. The episode will examine the structure, tone, and content of competitor access messaging, including AMCP dossiers, value decks, and in-field conversations. Lumara’s team must develop a differentiated and credible payer narrative — one that can cut through entrenched positioning and resonate with pharmacy and medical directors.Target Listener Persona:VP/Director of Market Access MarketingHEOR leads responsible for value story developmentPayer strategy and ac...
2025-10-2815 minThe Lumara SeriesEpisode 3: Patient Support Showdown –– HUBs, Copays, and Frictionless StartsPatient Support Showdown — HUBs, Copays, and Frictionless StartsEpisode 3 zeroes in on the first-fill moment and early adherence—where HUB design, copay policy, and specialty-pharmacy handoffs can make or break momentum. We unpack the essentials of high-performing programs (benefits investigation, real-time PA tracking, FRM support, nurse case management, and digital enrollment) and spotlight where patients and offices most often stall. You’ll hear how leading severe-asthma brands approach onboarding today, what providers say about enrollment friction, and why time to first dose—often 10–18 days—has become the metric that moves share. We also explore pract...
2025-10-2014 minThe Lumara SeriesEpisode 2: The Coverage ChessboardThe Coverage Chessboard — Formulary Status and Rebate WarsEpisode 2 dives into the real engine of access: how plans decide who gets preferred, who gets blocked, and what it really costs to move tiers. We unpack the payer dynamics shaping severe asthma today—tiering norms, step edits, and prior auth criteria—then walk through what wins preferred placement: net price after rebates, label breadth and real-world outcomes, ease of administration, and the quality of patient services. You’ll also hear how the competitive set (Dupixent, Tezspire, Fasenra, Nucala) influences plan logic across Commercial, Medicare Part D, Medicaid...
2025-10-1311 minThe Lumara SeriesEpisode 1: Meet LumaraMeet Lumara: A New Contender in Severe AsthmaIn Episode 1, we introduce Lumara—a fictional, once-monthly biologic with dual IL-5 and IL-13 inhibition—poised to enter a crowded severe-asthma market. With launch roughly 12 months out, early conversations with payers and providers have begun, and the competitive set—Dupixent, Fasenra, Tezspire, Nucala—is well established. We frame the stakes, surface emerging access vulnerabilities, and set the tone for an eight-part, intelligence-driven series built for time-constrained market access and brand leaders.What you’ll learnThe current ac...
2025-10-0317 minThe Lumara SeriesLumara Series Trailer: A GenAI-generated Podcast Series Demo for Specialty PharmaA Genflare-produced Podcast Series. Series Title: The Lumara Series: A Competitive Intelligence Podcast for Market Access and Brand Leaders in Specialty PharmaSeries Overview:The Lumara Series is an 8-episode, TA-specific competitive intelligence podcast produced by Genflare using commercially available GenAI tooling and systems to both generate all of the underlying content and sciences as well as the 2-speaker (podcast format) audio files that make up each of the episodes in the series. The series follows the hypothetical launch journey of Lumara, a fictional monoclonal a...
2025-09-1003 min